Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Five patients with common variable immunodeficiency treated in our hospital between December 1979 and December 1990 were given six kinds of intravenous immunoglobulin preparations (pepsin treated, S-sulfonated, polyethylene glycol treated, pH4 treated, alkylated, and pH4.25 formulation preparation) for replacement therapy. Duration of the therapy ranged from 7.6 to 11 years. Incidences of fever and acute infections were variable among patients, but no significant differences were seen in the incidences among periods given each preparation. Three cases revealed abnormal pulmonary functions in tests. Adverse reactions were rarely seen in our study periods, and no severe reactions were observed. No significant differences were seen in incidences of adverse reactions. Postinfusion levels of serum complement slightly decreased from preinfusion levels. However, the decrease in complement was not related to any adverse reaction. No long-term complications such as transmission of hepatitis have been observed. Our data suggest that no obvious differences exist between the efficacy and safety of each IVIG preparation. Differences of efficacy of IVIG replacement therapy may be due to the variable pathophysiology of each patient.
 ...
PMID:Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: reevaluation of intravenous immunoglobulin replacement therapy. IVIG therapy in CVID. 780 89

Albumin solutions invariably transmitted infectious hepatitis viruses before the introduction of pasteurisation in the final container. Immunoglobulin solutions (the older intramuscular as well as the current intravenous ones), on the other hand, only rarely transmitted hepatitis. The apparent safety of the latter was usually attributed to the presence of neutralizing antibodies and to the fractionation process. It was shown that viruses tend to concentrate in those fractions of the cold ethanol precipitation procedure which are used neither for albumin nor for immunoglobulin preparations. Additionally, ethanol alone inactivates some viruses, albeit much less at low temperatures than at room temperature. According to EC-directives, all manufacturers of stable blood products must introduce production steps which inactivate viruses or they have to prove that certain production steps, which are already being used, do inactivate viruses. In either case, the inactivation has to be validated with appropriate experiments. Procedures that are now recognized as virucidal are, e.g., pasteurisation (i.e., heating of the liquid product at 60 degrees C for 10 hours), solvent/detergent (S/D) treatment, photodynamic treatment, or incubation at pH4 with pepsin.
 ...
PMID:Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation. 817 2

Intravenous human immunoglobulin of domestic production was subjected to validation studies. Tests were performed in the system of model viruses for pathogenic factors of the B and C types of hepatitis. For simulated immunoglobulin infections two lipid-enveloped viruses were chosen: the first DNA virus pseudorabies PR-75 (model for HBV) and the second-RNA virus Sindbis (model for HCV). The survival of viruses in particular stages of bio-globulin production was checked, showing that pepsin digestion led to full inactivation of both viruses. The total reduction of infective titers of model viruses during the whole process exceeded 10 logs. Thus we can conclude that the process of bio-globulin manufacturing ensures the elimination and inactivation of lipid-enveloped viruses.
 ...
PMID:[Viral validation of the bio-globulin production process]. 852 73

The involvement of inducible nitric oxide synthase (iNOS) and nitrotyrosine (NT) in pathogenesis of toxocaral granulomatous hepatitis (TGH) in a murine host was quantitatively determined by biochemical, parasitological, pathological, and immunohistochemical assessments in a 42-week investigation. Mice were sacrificed for serum collection and histological processing as well as acid-pepsin digestion of the liver in a larval recovery study. Significantly increased levels of total serum NO were found in the trial, indirectly suggesting iNOS activation in the liver. iNOS reactivity was predominantly observed in infiltrating leucocytes in lesions and normal and apocrine-like cholangiocytes; in contrast, hepatocytes and multinucleated giant cells showed negative cytoplasmic staining in TGH. Strong iNOS-like reactivity was also detected on the body wall of larvae. The locations of NT reactivity were nearly identical to those of iNOS expression; infiltrating leucocytes or cholangiocytes stained for iNOS were also stained for NT in TGH. Enhanced iNOS expression, but not invading larvae (r = 0.256, P = 0.211), seemed to play a certain role in pathological damage in TGH due to a significant correlation between iNOS expression and serum alanine aminotransferase (ALT) levels (r =0.593, P = 0.021) in the trial. Our present results indicate a potential therapeutic strategy for treatment of GH caused by other nematodes through manipulation of iNOS expression.
 ...
PMID:Enhanced inducible nitric oxide synthase expression and nitrotyrosine accumulation in experimental granulomatous hepatitis caused by Toxocara canis in mice. 1554 Oct 31


<< Previous 1 2